AmCad BioMed Corporation (4188) Stock Overview

AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases, such as thyroid cancers, fatty liver, liver fibrosis, and obstructive sleep apnea. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-CA, a software device for analyzing digital cytological images; AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UV, a software device for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals. The company was incorporated in 2008 and is based in Taipei City, Taiwan.